share_log

Even Though Inspire Medical Systems (NYSE:INSP) Has Lost US$332m Market Cap in Last 7 Days, Shareholders Are Still up 177% Over 5 Years

Even Though Inspire Medical Systems (NYSE:INSP) Has Lost US$332m Market Cap in Last 7 Days, Shareholders Are Still up 177% Over 5 Years

儘管 inspire medical systems (紐交所:INSP)在過去7天中市值下降了US$33200萬,但股東在過去5年中仍獲得了177%的回報。
Simply Wall St ·  09/04 20:46

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For instance, the price of Inspire Medical Systems, Inc. (NYSE:INSP) stock is up an impressive 177% over the last five years. And in the last month, the share price has gained 18%.

在任何股票上你最多能虧損100%的資金(假設你不使用槓桿)。但當你選擇一家真正蓬勃發展的公司時,你可能會獲得超過100%的利潤。例如,過去五年來,Inspire Medical Systems, Inc.(紐交所:INSP)股票的價格上漲了驚人的177%。而在過去一個月裏,股價上漲了18%。

Since the long term performance has been good but there's been a recent pullback of 5.9%, let's check if the fundamentals match the share price.

由於長期表現良好,但最近出現了5.9%的回調,請檢查基本面是否與股價相匹配。

We don't think that Inspire Medical Systems' modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. It would be hard to believe in a more profitable future without growing revenues.

我們認爲,目前市場並沒有充分關注Inspire Medical Systems去年的適度盈利。我們認爲營業收入可能是更好的指標。一般來說,我們會將這樣的股票與虧損公司放在一起,僅僅是因爲盈利量很低。如果沒有不斷增長的營業收入,很難相信未來會有更多利潤。

In the last 5 years Inspire Medical Systems saw its revenue grow at 46% per year. That's well above most pre-profit companies. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 23% per year, compound, during the period. So it seems likely that buyers have paid attention to the strong revenue growth. To our minds that makes Inspire Medical Systems worth investigating - it may have its best days ahead.

在過去5年中,Inspire Medical Systems的營業收入年均增長46%。這遠高於大多數無利潤的公司。與此同時,股價表現確實反映了強勁的增長,因爲股價在這段時期內以年均23%的複合增長率增長。因此,似乎買家們已經注意到了強勁的營業收入增長。我們認爲這使得Inspire Medical Systems值得調查,它可能擁有最好的日子。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。

big
NYSE:INSP Earnings and Revenue Growth September 4th 2024
NYSE:INSP收益和營收增長2024年9月4日

Inspire Medical Systems is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

inspire medical systems在投資者中非常知名,許多聰明的分析師都嘗試過預測未來的利潤水平。因此我們建議您查看這份顯示共識預測的免費報告。

A Different Perspective

不同的觀點

Investors in Inspire Medical Systems had a tough year, with a total loss of 24%, against a market gain of about 23%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 23% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 1 warning sign for Inspire Medical Systems that you should be aware of.

inspire medical systems的投資者遭遇了困難的一年,總虧損達到了24%,而市場增長大約23%。然而,要記住,即使是最好的股票有時也會在一年的時間裏表現不佳。但好消息是,長期股東獲得了收益,在過去的五年裏,年收益率爲23%。最近的拋售可能是一個機會,所以值得檢查基本數據,看看是否有長期增長趨勢的跡象。考慮到市場條件對股價的影響是非常值得考慮的,但還有其他更重要的因素。例如,我們已經找到了一項對inspire medical systems的警告信號,您應該注意。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果您願意查看另一家公司(具有潛在的更好財務狀況),請不要錯過這個免費的公司列表,證明它們可以增長收益。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論